한글목차

혈관조영 장비 시장은 2022년에는 149억 200만 달러로 평가되었고 복합 연간 성장률(CAGR) 8.42%로 성장할 전망이며 2029년에는 262억 3,600만 달러에 이를 것으로 예측됩니다.

혈관 조영술은 혈관을 시각화하고 혈류를 평가하는 데 사용되는 의료 기술입니다. 조영제를 혈관에 주입하고, X선 영상을 촬영하여 상세한 영상을 얻는다. 종래의 혈관 조영술은 전리 방사선을 사용하지만, 디지털 서브트랙션 혈관 조영술은 가시성을 증가시킵니다. 투시 시스템은 연속 X 선 빔을 사용하여 실시간 이미지를 얻을 수 있습니다.

조영제에는 요오드계나 신형의 것이 사용됩니다. 비침습적인 방법으로는 컴퓨터 단층촬영법(CTA), 자기공명혈관촬영법(MRA), 초음파 시스템, 혈행동태 모니터링 시스템 등이 있습니다. 고급 혈관조영 장비에는 3D 재구성 소프트웨어가 포함됩니다. 세계에서 암과 심혈관 질환의 이환율이 증가하고 있는 것이 예측 기간 동안 혈관조영 장비 시장의 성장을 가속할 것으로 예상되는 주요 요인 중 하나입니다.

영문목차

The angiography equipment market is evaluated at US$14.902 billion for 2022 and is projected to grow at a CAGR of 8.42% to reach US$26.236 billion by 2029.

Angiography is a medical technique used to visualize blood vessels and assess blood flow. It involves injecting a contrast agent into blood vessels and capturing X-ray images to obtain detailed images. Traditional angiography uses ionizing radiation, while Digital Subtraction Angiography enhances visibility. Fluoroscopy systems use continuous X-ray beams for real-time images.

Contrast agents, such as iodine-based or newer ones, are used. Non-invasive alternatives include Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA), ultrasound systems, and hemodynamic monitoring systems. Advanced angiography equipment includes 3D reconstruction software. The high prevalence, coupled with the increasing incidence of cancer and cardiovascular diseases around the world, is one of the major factors anticipated to drive the angiography equipment market growth during the forecast period.

The rise in the geriatric population and an increase in the growing number of obese people worldwide are leading to a surge in diseases that require angiography. Furthermore, favorable government regulations for the approval of the product in the various developed regions are also expected to fuel the growth of the global market. There is also a growing demand for angiography systems due to a shift in preference toward minimally invasive surgeries.

Moreover, growing innovations in angiography equipment are improving the medical process and, hence, are anticipated to contribute to the market growth. However, high costs associated with the procurement and use of technologically advanced angiography equipment are major factors likely to hamper the global market growth.

Market Drivers:

• The increasing prevalence of cardiovascular diseases is anticipated in the market growth

The world has witnessed a surge in the number of cases of cardiovascular diseases over the years, which is leading to an increased demand for angiography equipment and is projected to boost market growth during the forecast period. A paper in the Journal of the American College of Cardiology stated in December 2020 that there were 270 million cases of cardiovascular diseases in 1990, which nearly doubled to 523 million in 2019. It also states that the number of people who died from cardiovascular disease increased from 12.1 million in 1990 to 18.6 million in 2019.

The American Heart Association (AHA) predicts that 45% of the population of the United States will have at least one heart-related problem. It also estimates that the costs related to cardiovascular diseases will increase by 100% between 2016 and 2035. According to WHO, cardiovascular disease has the highest share in the list of leading causes of death.

The organization states that cardiovascular diseases caused 17.9 million deaths in 2019 around the world and represented 32% of all deaths worldwide. Premature deaths are also increasing with the growing prevalence of heart diseases, with 38% of all the 17 million premature deaths due to non-communicable diseases caused by CVDs in 2019. The growing trend of CVDs is projected to continue in the coming years as well and is anticipated to drive the market growth of angiography equipment.

• An increase in innovation would bolster the angiography equipment market.

The rising innovations in the market and the launch of advanced angiography equipment by the market players are widening the scope of angiography equipment and are anticipated to propel the growth of angiography equipment during the assessment period. The medical device company Kinepict Health has developed Kinepict Medical Imaging Tool (KMIT) software which uses Digital Variance Angiography (DVA) technology and provides superior image quality compared to the conventionally used technologies.

The FDA has given clearance for it in March 2020, allowing it to be launched in the U.S. market. Furthermore, GE Healthcare introduced the Allia IGS 7 angiography system at the Radiological Society of North America (RSNA) 2020 virtual meeting. The system uses artificial intelligence and allows better use of rotational angiography.

Various companies are launching several other innovative products that will improve the angiography process and are anticipated to spur the growth of angiography equipment during the forecast period.

North America region held a significant market share.

The North American region is anticipated to hold a significant market share owing to the presence of a large number of market leaders, coupled with a high prevalence of cardiovascular diseases. The presence of an advanced healthcare system also allows a larger adoption of new and advanced angiography equipment.

The region is anticipated to witness substantial growth due to the rising number of cases of CVDs, coupled with increased investments in the healthcare sector in the region, which will lead to the availability of requisite healthcare facilities.

Key Developments:

• July 2023- Siemens Healthineers introduced the Atellica CI Analyzer, a compact testing system designed to address lab challenges. The FDA-cleared analyzer offers improved turnaround time predictability, advanced reporting functionality, and safety measures. It is suitable for low to medium testing volumes and is now available in many major markets. Siemens Healthineers also launched the Atellica Vantage 640 Cardiac Angiography System, which offers superior image quality and faster scan times for complex cardiac procedures. Philips Healthcare's Azurion Clarity 3D angiography system provides real-time 3D images of blood vessels, while GE Healthcare's Discovery(TM) HI FX40 angiography system offers high-quality images at low radiation doses.
• May 2023- GE HealthCare's Voluson(TM) Expert 22 was named the "Best New Ultrasound Technology Solution" at the seventh annual MedTech Breakthrough Awards. The device, which uses an adaptive graphic-based beamformer and artificial intelligence, aids in over 3.6 million live births annually in the US. Its Lyric Architecture enables real-time data processing, resulting in sharper imaging in 2D/3D/4D. The device also features a user-friendly touch panel display, simple controls, and a high-definition ultrasound monitor with three image sizes. Clinicians can personalize the display and controls with exterior lighting colors, trackballs, and hard and soft keys.
• November 2022- Canon Inc. developed the first domestically produced photon-counting CT (PCCT) system, incorporating Redlen Technologies Inc.'s advanced technologies. The system, installed at the National Cancer Center Japan Exploratory Oncology Research & Clinical Trial Center, is used for research exploring the clinical applications of PCCT. The system features an advanced modular photon-counting detector based on the latest crystal production/processing technologies developed by Redlen Technologies Inc., which allows for increased size while reducing manufacturing and service costs.

Market Segmentation:

By Technology

• X-Ray Angiography
• Computed Tomography Angiography
• Magnetic Resonance Angiography

By Procedure

• Coronary
• Endovascular
• Neurovascular

By Application

• Diagnostic
• Therapeutic

By End-User

• Hospitals and Clinics
• Research Institutes
• Diagnostic Centers

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• UK
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. ANGIOGRAPHY EQUIPMENT MARKET BY TECHNOLOGY

• 5.1. Introduction
• 5.2. X-Ray Angiography
  • 5.2.1. Market Opportunities and Trends
  • 5.2.2. Growth Prospects
  • 5.2.3. Geographic Lucrativeness
• 5.3. Computed Tomography Angiography
  • 5.3.1. Market Opportunities and Trends
  • 5.3.2. Growth Prospects
  • 5.3.3. Geographic Lucrativeness
• 5.4. Magnetic Resonance Angiography
  • 5.4.1. Market Opportunities and Trends
  • 5.4.2. Growth Prospects
  • 5.4.3. Geographic Lucrativeness

6. ANGIOGRAPHY EQUIPMENT MARKET BY PROCEDURE

• 6.1. Introduction
• 6.2. Coronary
  • 6.2.1. Market Opportunities and Trends
  • 6.2.2. Growth Prospects
  • 6.2.3. Geographic Lucrativeness
• 6.3. Endovascular
  • 6.3.1. Market Opportunities and Trends
  • 6.3.2. Growth Prospects
  • 6.3.3. Geographic Lucrativeness
• 6.4. Neurovascular
  • 6.4.1. Market Opportunities and Trends
  • 6.4.2. Growth Prospects
  • 6.4.3. Geographic Lucrativeness

7. ANGIOGRAPHY EQUIPMENT MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Diagnostic
  • 7.2.1. Market Opportunities and Trends
  • 7.2.2. Growth Prospects
  • 7.2.3. Geographic Lucrativeness
• 7.3. Therapeutic
  • 7.3.1. Market Opportunities and Trends
  • 7.3.2. Growth Prospects
  • 7.3.3. Geographic Lucrativeness

8. ANGIOGRAPHY EQUIPMENT MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospitals & Clinics
  • 8.2.1. Market Opportunities and Trends
  • 8.2.2. Growth Prospects
  • 8.2.3. Geographic Lucrativeness
• 8.3. Research Institutes
  • 8.3.1. Market Opportunities and Trends
  • 8.3.2. Growth Prospects
  • 8.3.3. Geographic Lucrativeness
• 8.4. Diagnostic Centers
  • 8.4.1. Market Opportunities and Trends
  • 8.4.2. Growth Prospects
  • 8.4.3. Geographic Lucrativeness

9. ANGIOGRAPHY EQUIPMENT MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Technology
  • 9.2.2. By Procedure
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
      • 9.2.5.1.1. Market Opportunities and Trends
      • 9.2.5.1.2. Growth Prospects
    • 9.2.5.2. Canada
      • 9.2.5.2.1. Market Opportunities and Trends
      • 9.2.5.2.2. Growth Prospects
    • 9.2.5.3. Mexico
      • 9.2.5.3.1. Market Opportunities and Trends
      • 9.2.5.3.2. Growth Prospects
• 9.3. South America
  • 9.3.1. By Technology
  • 9.3.2. By Procedure
  • 9.3.3. By Application
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
      • 9.3.5.1.1. Market Opportunities and Trends
      • 9.3.5.1.2. Growth Prospects
    • 9.3.5.2. Argentina
      • 9.3.5.2.1. Market Opportunities and Trends
      • 9.3.5.2.2. Growth Prospects
    • 9.3.5.3. Others
      • 9.3.5.3.1. Market Opportunities and Trends
      • 9.3.5.3.2. Growth Prospects
• 9.4. Europe
  • 9.4.1. By Technology
  • 9.4.2. By Procedure
  • 9.4.3. By Application
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. Germany
      • 9.4.5.1.1. Market Opportunities and Trends
      • 9.4.5.1.2. Growth Prospects
    • 9.4.5.2. France
      • 9.4.5.2.1. Market Opportunities and Trends
      • 9.4.5.2.2. Growth Prospects
    • 9.4.5.3. UK
      • 9.4.5.3.1. Market Opportunities and Trends
      • 9.4.5.3.2. Growth Prospects
    • 9.4.5.4. Spain
      • 9.4.5.4.1. Market Opportunities and Trends
      • 9.4.5.4.2. Growth Prospects
    • 9.4.5.5. Others
      • 9.4.5.5.1. Market Opportunities and Trends
      • 9.4.5.5.2. Growth Prospects
• 9.5. Middle East and Africa
  • 9.5.1. By Technology
  • 9.5.2. By Procedure
  • 9.5.3. By Application
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
      • 9.5.5.1.1. Market Opportunities and Trends
      • 9.5.5.1.2. Growth Prospects
    • 9.5.5.2. UAE
      • 9.5.5.2.1. Market Opportunities and Trends
      • 9.5.5.2.2. Growth Prospects
    • 9.5.5.3. Others
      • 9.5.5.3.1. Market Opportunities and Trends
      • 9.5.5.3.2. Growth Prospects
• 9.6. Asia Pacific
  • 9.6.1. By Technology
  • 9.6.2. By Procedure
  • 9.6.3. By Application
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
      • 9.6.5.1.1. Market Opportunities and Trends
      • 9.6.5.1.2. Growth Prospects
    • 9.6.5.2. India
      • 9.6.5.2.1. Market Opportunities and Trends
      • 9.6.5.2.2. Growth Prospects
    • 9.6.5.3. Japan
      • 9.6.5.3.1. Market Opportunities and Trends
      • 9.6.5.3.2. Growth Prospects
    • 9.6.5.4. South Korea
      • 9.6.5.4.1. Market Opportunities and Trends
      • 9.6.5.4.2. Growth Prospects
    • 9.6.5.5. Taiwan
      • 9.6.5.5.1. Market Opportunities and Trends
      • 9.6.5.5.2. Growth Prospects
    • 9.6.5.6. Thailand
      • 9.6.5.6.1. Market Opportunities and Trends
      • 9.6.5.6.2. Growth Prospects
    • 9.6.5.7. Indonesia
      • 9.6.5.7.1. Market Opportunities and Trends
      • 9.6.5.7.2. Growth Prospects
    • 9.6.5.8. Others
      • 9.6.5.8.1. Market Opportunities and Trends
      • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. GE Healthcare
• 11.2. Siemens Healthcare
• 11.3. Philips Healthcare
• 11.4. Shimadzu Corporation
• 11.5. Canon Medical Systems Corporation
• 11.6. Carestream Health
• 11.7. B. Braun Melsungen AG
• 11.8. Boston Scientific Corporation
• 11.9. Cordis Corporation
• 11.10. AngioDynamics, Inc.